Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 24Genitourinary 3Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Carcinoma, Hepatocellular 222Liver Neoplasms 68Neoplasms 18Pancreatic Neoplasms 16Neoplasm Metastasis 14Colorectal Neoplasms 12Rectal Neoplasms 8Stomach Neoplasms 7Colonic Neoplasms 7Carcinoma, Renal Cell 6Carcinoma 6Liver Diseases 5Gallbladder Neoplasms 5Breast Neoplasms 5Digestive System Neoplasms 4Bile Duct Neoplasms 4Prostatic Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Melanoma 2Hepatoblastoma 2Hepatitis C 2Hepatitis B 2Hematologic Neoplasms 2Glioblastoma 2

Interventions

pembrolizumab 59Nivolumab 34Cyclophosphamide 21fludarabine 15Paclitaxel 12Ipilimumab 12atezolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Carboplatin 10Docetaxel 9Cisplatin 9Gemcitabine 8Biopsy 8durvalumab 7aldesleukin 7Radiosurgery 7Interleukin-2 7Bevacizumab 7cemiplimab 6Pemetrexed 6fludarabine phosphate 5avelumab 5Radiotherapy 5Drug Therapy 5spartalizumab 4epacadostat 4enzalutamide 4Taxes 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Sorafenib × Gastrointestinal × Clear all
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡